Last updated: September 5, 2026
The prednisolone acetate and sulfacetamide sodium ophthalmic combination is a mature prescription eye-drop product sold primarily as Blephamide and authorized generic or generic equivalents. Its commercial profile is defined by low clinical differentiation, long-established generic competition, limited public revenue disclosure, and minimal remaining regulatory exclusivity. The combination is used for steroid-responsive ocular inflammation when bacterial infection or a risk of bacterial infection is present [1].
What is the prednisolone acetate and sulfacetamide sodium product?
The product combines:
| Component |
Concentration in Blephamide suspension |
Pharmacologic role |
| Prednisolone acetate |
0.2% |
Corticosteroid that reduces ocular inflammation |
| Sulfacetamide sodium |
10% |
Sulfonamide antibacterial |
Blephamide is available as an ophthalmic suspension and ointment. The suspension requires shaking before use because prednisolone acetate is poorly water-soluble and remains dispersed rather than fully dissolved [1].
The FDA-approved indication is steroid-responsive inflammatory ocular conditions in which a superficial bacterial infection exists or a risk of bacterial infection is present. The label limits use to conditions where the anti-inflammatory benefit justifies the risk of corticosteroid treatment [1].
The product is not interchangeable with either ingredient used alone. Prednisolone acetate ophthalmic products compete on anti-inflammatory efficacy, while sulfacetamide-containing antibiotic products compete on antibacterial coverage and price.
What is the FDA regulatory status of Blephamide and generic equivalents?
Blephamide is an established prescription ophthalmic drug. Its regulatory history predates the modern generic-drug market, and generic versions can be approved through abbreviated new drug applications if they demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.
Key regulatory characteristics
| Regulatory issue |
Market implication |
| Prescription-only status |
Limits direct-to-consumer volume but preserves physician and pharmacy channel control |
| Ophthalmic suspension dosage form |
Creates manufacturing and quality-control requirements beyond a simple solution |
| Combination product |
Requires equivalence for both active ingredients and the finished dosage form |
| Sterile ophthalmic delivery |
Raises compliance costs and increases the impact of manufacturing disruptions |
| No biologic component |
No biosimilar pathway applies |
| Mature active ingredients |
Limits clinical differentiation and pricing power |
The combination is regulated as a conventional small-molecule ophthalmic product, not as a biologic. Biosimilar competition therefore is not relevant. Competitive risk comes from generic ANDA applicants, authorized generics, therapeutic substitutes and pharmacy-level product switching.
FDA labeling warns against prolonged corticosteroid use because of risks including elevated intraocular pressure, glaucoma, cataract formation, delayed healing and secondary infection [1]. These safety considerations support prescription control but do not create meaningful market exclusivity.
When does prednisolone acetate and sulfacetamide sodium lose exclusivity?
The product has already lost the commercial exclusivity that would normally support branded pricing. Its market is post-exclusivity and genericized.
Exclusivity timeline
| Period |
Commercial position |
| Original launch period |
Branded combination with limited direct competition |
| Patent and regulatory exclusivity period |
Potential protection for formulation, manufacturing or labeling claims |
| Generic entry period |
ANDA-based competition begins |
| Current market |
Mature generic market with price pressure and limited brand leverage |
Exact launch and patent dates differ by dosage form and product presentation. The core combination is old, and current commercial value does not depend on a surviving composition-of-matter patent.
FDA Orange Book records are the relevant source for active patents and regulatory exclusivity associated with a listed product. For a mature product such as Blephamide, the principal commercial issue is usually the number and reliability of approved suppliers rather than patent duration [2].
What patents protect prednisolone acetate and sulfacetamide sodium?
The patent estate is commercially weak relative to newer ophthalmic products. The active ingredients are long-established compounds, so composition-of-matter protection is not a current barrier to generic entry.
Potential historical or secondary protection could have covered:
- Ophthalmic suspension formulations
- Preservative systems
- Particle-size control
- Manufacturing and sterilization processes
- Container-closure systems
- Dosing or administration methods
- Labeling directed to specific inflammatory or infectious conditions
These categories generally do not provide durable exclusivity for a mature ophthalmic combination unless they are listed in the Orange Book, remain unexpired and are difficult to design around.
Patent-strength assessment
| Patent category |
Current strength |
| Active-ingredient patents |
Very weak or expired |
| Basic combination patent |
Very weak or expired |
| Suspension formulation patents |
Potentially relevant but usually narrow |
| Method-of-use patents |
Limited value unless listed and enforceable |
| Manufacturing patents |
Can create operational friction but rarely block all generic entry |
| Device or container patents |
Usually low impact for this product |
| Regulatory exclusivity |
Not a current commercial driver |
A generic applicant would normally address any listed patent through a Paragraph III certification, Paragraph IV certification, or a statement that no relevant patent is listed, depending on the Orange Book record. Because the combination is mature, a new Paragraph IV event would more likely concern a narrow formulation or process patent than the underlying active ingredients.
Which companies are challenging Blephamide market share?
Competition is spread across branded, authorized-generic and generic suppliers. The principal commercial participants include:
- AbbVie, through the legacy Allergan branded portfolio
- Generic ophthalmic manufacturers with ANDA-approved prednisolone acetate and sulfacetamide sodium products
- Contract manufacturers supplying sterile ophthalmic suspensions
- Manufacturers of single-ingredient alternatives
- Retail and mail-order pharmacies using formulary substitution
Public disclosures do not isolate sales of Blephamide or its generic equivalents. AbbVie reports revenue by broader product categories and major brands rather than providing a standalone revenue line for this combination [3].
What is the Orange Book status of prednisolone acetate and sulfacetamide sodium?
The Orange Book is the controlling reference for listed patents, therapeutic equivalence evaluations and approved drug products. For a mature ophthalmic combination, the important questions are whether:
- The reference listed drug has active patent listings.
- Generic products have an “A”-rated therapeutic-equivalence code.
- Approved ANDAs cover the same concentration and dosage form.
- Any patent litigation has delayed approval or launch.
- A product is an authorized generic rather than an independently marketed ANDA product.
The practical market position is consistent with a post-exclusivity product. FDA-approved equivalents can compete on price, availability and pharmacy contracting without waiting for a new clinical development program.
Are there Paragraph IV challenges or patent litigation?
No major, publicly prominent patent litigation currently defines the commercial position of prednisolone acetate and sulfacetamide sodium. That outcome is consistent with an old combination whose principal active-ingredient patents have expired.
Paragraph IV litigation is more likely when a branded product has:
- High annual sales
- Few approved suppliers
- A recent formulation patent
- A high-value delivery technology
- A substantial difference between branded and generic pricing
This combination lacks most of those characteristics. A narrow dispute over suspension characteristics, preservative concentration or manufacturing parameters could occur, but such a dispute would not necessarily prevent other manufacturers from supplying the market.
There is no known biosimilar litigation pathway because the product is a small-molecule drug. Any litigation risk is conventional Hatch-Waxman or commercial patent litigation.
What formulations are protected by the product?
The principal dosage forms are ophthalmic suspension and ophthalmic ointment. The suspension creates more technical risk than a simple ophthalmic solution because performance depends on:
- Uniform distribution of prednisolone acetate particles
- Controlled particle size
- Physical stability over shelf life
- Adequate redispersibility after shaking
- Sterility
- Preservative effectiveness
- Drop-size consistency
- Compatibility with the container and closure
These characteristics can create manufacturing barriers without creating durable patent exclusivity. A company may need validated sterile manufacturing capacity, specialized suspension-processing controls and stability data. Those requirements can reduce the number of reliable suppliers, especially during plant outages or quality investigations.
The formulation is therefore more operationally defensible than legally defensible. Manufacturing competence may support intermittent pricing power, but it does not establish a durable moat.
How strong is the patent estate compared with newer ophthalmic drugs?
| Product type |
Patent strength |
Pricing power |
Generic-entry risk |
| Prednisolone acetate/sulfacetamide sodium |
Low |
Low |
High |
| New branded ophthalmic suspension |
Moderate to high |
Moderate to high |
Moderate |
| Branded ophthalmic delivery system |
High if device or formulation patents survive |
High |
Lower |
| Biologic ophthalmic therapy |
Often high |
High |
Biosimilar-dependent |
| Single-ingredient generic steroid |
Low |
Low |
High |
Newer ophthalmic products often rely on proprietary vehicles, reduced-dosing formulations, sustained-release inserts, preservative-free packaging or novel delivery systems. Prednisolone acetate and sulfacetamide sodium do not have comparable platform protection.
What is the market outlook and financial trajectory?
The financial trajectory is mature-to-declining in nominal branded terms, with stable underlying demand but continuing price erosion. Public companies do not separately report revenue, prescription volume or gross margin for the combination. A precise product-level revenue estimate therefore is not supported by public filings.
Revenue drivers
| Driver |
Directional effect |
| Generic substitution |
Negative for branded revenue |
| Chronic ophthalmic disease prevalence |
Supports baseline demand |
| Short treatment duration |
Limits recurring revenue |
| Low-cost alternatives |
Pressures net pricing |
| Pharmacy formulary control |
Favors lowest-cost suppliers |
| Sterile manufacturing shortages |
Can temporarily improve pricing |
| Physician preference for combination therapy |
Supports niche demand |
| Corticosteroid safety monitoring |
Limits prolonged use |
The market is primarily episodic. Prescriptions are tied to postoperative inflammation, conjunctival or corneal inflammation, blepharitis-related conditions and other steroid-responsive ocular disorders where antibacterial coverage is considered appropriate. The product does not have the recurring refill profile of chronic glaucoma, diabetes or autoimmune medicines.
Financial scenario
| Scenario |
Expected commercial result |
| Base case |
Stable low-value demand, declining branded share and continued generic price pressure |
| Upside case |
Temporary price improvement caused by supplier exits or sterile-product shortages |
| Downside case |
Further substitution by generic steroid products, antibiotic-steroid alternatives or separate-component therapy |
| Strategic acquisition case |
Limited value unless bundled into a broader ophthalmic portfolio |
| Manufacturing disruption case |
Short-term volume and price volatility rather than durable market expansion |
The strongest economic asset may be reliable supply rather than patent ownership. A manufacturer with validated sterile ophthalmic capacity can capture share during shortages, but that advantage depends on quality compliance, inventory and contracting.
What generic launch risks exist?
Generic entry risk is high because the combination is mature and clinically familiar. A new entrant would face technical rather than fundamental legal barriers.
Generic-launch considerations
- Demonstrating pharmaceutical equivalence for both actives
- Matching suspension performance
- Establishing sterility and preservative effectiveness
- Securing reliable ophthalmic filling capacity
- Managing low average selling prices
- Obtaining pharmacy and wholesaler access
- Competing against incumbent suppliers with existing contracts
- Avoiding manufacturing interruptions and FDA warning-letter exposure
The main risk for a new entrant is economic. Development and validation costs can be meaningful for a sterile suspension, while market prices may be too low to support many suppliers. That dynamic can produce a concentrated supplier base even when patent protection is absent.
What licensing deals affect the product?
No major recent licensing transaction appears to determine the commercial outlook for prednisolone acetate and sulfacetamide sodium. Legacy brand ownership has moved through broader ophthalmology portfolio transactions, including the transfer of Allergan’s business to AbbVie. Such portfolio-level transactions do not establish new exclusivity for this mature combination [3].
Licensing value would generally be limited to:
- Regional commercialization rights
- Authorized-generic supply
- Contract manufacturing
- Distribution agreements
- Portfolio bundling with other ophthalmic products
The product is unlikely to attract standalone licensing premiums comparable to patented ophthalmic therapies.
What geographic markets are most relevant?
The United States is the most important market for Orange Book analysis and Hatch-Waxman litigation. Outside the United States, market access depends on national registration, local generic substitution rules, reimbursement and tender systems.
| Region |
Main commercial issue |
| United States |
ANDA competition, Orange Book status and pharmacy substitution |
| European Union |
National pricing, generic authorization and reimbursement |
| Canada |
Provincial reimbursement and generic substitution |
| Latin America |
Local registration, branded-generics and distributor access |
| Asia-Pacific |
Price-sensitive tenders and local manufacturing |
Geographic revenue is not separately disclosed for the combination. In lower-price markets, the product competes as a commodity ophthalmic medicine. In regulated reimbursement systems, formulary placement and supply reliability matter more than brand recognition.
Key Takeaways
- Prednisolone acetate and sulfacetamide sodium is a mature ophthalmic combination with little remaining exclusivity value.
- Blephamide and generic equivalents compete in a price-sensitive prescription market.
- The active ingredients do not provide current composition-of-matter protection.
- Formulation and sterile-manufacturing requirements create operational barriers but generally do not create durable legal exclusivity.
- Biosimilar risk does not apply because the product is a conventional small-molecule drug.
- No major current patent litigation is known to define the market.
- Product-level revenue is not separately disclosed by major public companies.
- The likely financial trajectory is stable-to-declining branded revenue, with occasional short-term pricing gains during supply disruptions.
- Manufacturing reliability, pharmacy contracting and supplier availability are more important than patent strength.
FAQs
Is Blephamide still commercially available?
Blephamide and generic prednisolone acetate/sulfacetamide sodium products have been marketed as prescription ophthalmic products, although availability can vary by dosage form, manufacturer and wholesaler inventory.
Is prednisolone acetate and sulfacetamide sodium the same as Maxitrol?
No. Blephamide contains prednisolone acetate and sulfacetamide sodium. Maxitrol contains dexamethasone with neomycin and polymyxin B. They differ in steroid potency, antibacterial components and labeling.
Can a generic company launch without challenging a patent?
Yes. A company may file an ANDA with a Paragraph III certification, a patent statement or another applicable certification if no blocking unexpired patent prevents approval. A Paragraph IV certification is required only when the applicant contests a listed patent.
Does the combination have orphan-drug or pediatric exclusivity?
The product is not generally associated with current orphan-drug exclusivity. Pediatric exclusivity, if historically granted for a specific product, would not normally provide a meaningful current barrier for this mature combination.
Why can a generic ophthalmic suspension remain expensive despite expired patents?
Sterile manufacturing, suspension uniformity, quality testing, limited filling capacity and supplier exits can keep prices above those of ordinary oral generics. The constraint is manufacturing economics rather than patent protection.
References
- U.S. Food and Drug Administration. (2023). Blephamide ophthalmic suspension prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- AbbVie Inc. (2024). 2023 annual report and Form 10-K.
